Literature DB >> 22682667

The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.

Andrea Billè1, Lawrence Okiror, Andrea Skanjeti, Luca Errico, Vincenzo Arena, Daniele Penna, Francesco Ardissone, Ettore Pelosi.   

Abstract

BACKGROUND: Integrated PET/CT is widely used in the preoperative staging and prognostic assessment of non-small-cell lung cancer (NSCLC) patients. The aims of this study were to evaluate the prognostic significance of SUVmax of primary tumor in patients undergoing surgical treatment and, in order to minimize technical interferences, to verify whether SUVmax standardized by SUVmax liver or SUVmax blood pool provided additional prognostic information. PATIENTS AND METHODS: A retrospective study of 413 consecutive NSCLC patients undergoing potentially curative surgical resection after PET/CT obtained in the same PET center over a 6-year period. The SUVmax was calculated drawing region of interest around the primitive tumor, the liver, and the aortic arch in PET images. The same procedure was performed for 2 adjacent planes and the average of these measures was considered.
RESULTS: Nine patients were considered 30-day postoperative deaths and were excluded from the analysis. At the end of the study, 312 (77.2%) of the 404 patients were alive (median follow-up, 26 months) and 92 had died (median survival, 17 months). At multivariate analysis tumor-node-metastasis stage, primary tumor grading and primary tumor SUVmax (T-SUVmax) were found to be independent prognostic factors, while T-SUVmax/SUVmax blood pool ratio, and T-SUVmax/SUVmax liver ratio were not.
CONCLUSIONS: T-SUVmax is an independent predictor for survival in NSCLC patients undergoing surgery and might be helpful in guiding adjuvant treatment strategies. SUVmax of primary tumor normalized by SUV blood pool or SUV liver does not provide additional prognostic information.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682667     DOI: 10.1016/j.cllc.2012.04.007

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  11 in total

1.  Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Authors:  Jens Köhler; Martin Schuler; Thomas Christoph Gauler; Stefanie Nöpel-Dünnebacke; Maike Ahrens; Andreas-Claudius Hoffmann; Stefan Kasper; Felix Nensa; Benedikt Gomez; Maria Hahnemann; Frank Breitenbuecher; Danjouma Cheufou; Filiz Özkan; Kaid Darwiche; Mathias Hoiczyk; Henning Reis; Stefan Welter; Wilfried Ernst Erich Eberhardt; Martin Eisenacher; Helmut Teschler; Georgios Stamatis; Wolff Schmiegel; Stephan Albrecht Hahn; Alexander Baraniskin
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-19       Impact factor: 4.553

2.  New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.

Authors:  Yang Wang; Ning Zhao; Zhanbo Wu; Na Pan; Xuejie Shen; Ting Liu; Feng Wei; Jian You; Wengui Xu; Xiubao Ren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-09       Impact factor: 9.236

3.  Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal (18)F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC).

Authors:  Gerald Sma Kerner; Alexander Fischer; Michel Jb Koole; Jan Pruim; Harry Jm Groen
Journal:  EJNMMI Res       Date:  2015-03-21       Impact factor: 3.138

Review 4.  Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jing Liu; Min Dong; Xiaorong Sun; Wenwu Li; Ligang Xing; Jinming Yu
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

5.  Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.

Authors:  Jinghua Chen; Junxian Xia; Jiacheng Huang; Ruilian Xu
Journal:  BMC Cancer       Date:  2020-06-03       Impact factor: 4.430

6.  Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.

Authors:  Kewei Zhao; Chunsheng Wang; Fang Shi; Yong Huang; Li Ma; Minghuan Li; Yipeng Song
Journal:  BMC Cancer       Date:  2021-01-14       Impact factor: 4.430

7.  Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study.

Authors:  Linping Ke; Lu Wang; Jinming Yu; Xue Meng
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

8.  Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.

Authors:  Minghui Zhang; Dalong Wang; Qi Sun; Haihong Pu; Yan Wang; Shu Zhao; Yan Wang; Qiangyuan Zhang
Journal:  Oncotarget       Date:  2017-05-29

9.  [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].

Authors:  Hongliang Ren; Wengui Xu; Jian You; Xiuyu Song; Hui Huang; Ning Zhao; Xiubao Ren; Xinwei Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-04-20

10.  Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.

Authors:  Tomoyuki Miyazawa; Kanji Otsubo; Hiroki Sakai; Hiroyuki Kimura; Motohiro Chosokabe; Kei Morikawa; Naoki Furuya; Hideki Marushima; Koji Kojima; Masamichi Mineshita; Junki Koike; Hisashi Saji
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.